Your browser is no longer supported. Please, upgrade your browser.
STTK Shattuck Labs, Inc. daily Stock Chart
Shattuck Labs, Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own0.90% Shs Outstand39.05M Perf Week7.05%
Market Cap794.28M Forward P/E- EPS next Y- Insider Trans- Shs Float33.49M Perf Month-
Income-27.40M PEG- EPS next Q- Inst Own- Short Float- Perf Quarter-
Sales10.80M P/S73.54 EPS this Y-224.60% Inst Trans- Short Ratio- Perf Half Y-
Book/sh- P/B- EPS next Y- ROA- Target Price- Perf Year-
Cash/sh3.78 P/C5.38 EPS next 5Y- ROE- 52W Range17.51 - 22.90 Perf YTD5.12%
Dividend- P/FCF- EPS past 5Y- ROI72.40% 52W High-8.12% Beta-
Dividend %- Quick Ratio10.50 Sales past 5Y- Gross Margin- 52W Low20.16% ATR1.71
Employees50 Current Ratio10.50 Sales Q/Q16.60% Oper. Margin- RSI (14)- Volatility5.52% -
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.17 Prev Close20.34
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume863.70K Price21.04
Recom- SMA207.14% SMA507.14% SMA2007.14% Volume145,192 Change3.44%
Oct-09-20 03:49PM  
Oct-08-20 07:55PM  
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian cancer. It also holds a collaboration agreement with Takeda Pharmaceuticals to develop SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was founded in 2016 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Redmile Group, LLCDirectorOct 14Buy17.343,441,17659,669,3435,619,914Oct 15 05:21 PM